Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 49

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
$(10,983)$(416,400)$141 $48,818 Net loss— — — (19,925)— (19,925)Stock-based compensation expense— 2,688 — — — 2,688 Issuance of common stock in exchange for consulting services— 193 — — — 193 Issuance of common stock as part of the Employee Stock Purchase Plan— 424 — — — 424 Other comprehensive income— — — — 280 280 Balance as of June 30, 2024$4 $479,361 $(10,983)$(436,325)$421 $32,478 

See accompanying notes to unaudited condensed consolidated financial statements.

8

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Six months ended June 30,20252024Cash flows from operating activities:Net income (loss)$71,608 $(36,547)Adjustments to reconcile net income (loss) to net cash used in operating activities:Stock-based compensation expense5,579 4,751 Impairment of intangible assets58,710 — Inventory obsolescence charge11,681 3,219 Income tax expense3,381 — Depreciation and amortization expense3,300 3,124 Non-cash interest expense1,352 710 Fair value adjustment related to warrant and CVR liability(4,127)(9,406)Accretion on investments(1,060)— Fair value adjustment related to investments5 26 Consulting fees paid in common stock75 249 Loss on foreign currency exchange rates131 188 Gain on sale of PRV(148,325)— Change in assets and liabilities:Accounts and other receivables(6,969)8,430 Prepaid expenses and other current assets(296)(862)Inventories(586)(3,576)Operating lease right-of-use assets(798)298 Accounts payable and accrued expenses(11,269)(8,602)Discount and rebate liabilities3,048 2,670 Operating lease liabilities746 (278)Other liabilities1,991 332 Net cash used in operating activities(11,823)(35,274)Cash flows from investing activities